Call Options

17 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$0.21 - $0.53 $4,137 - $10,441
-19,700 Reduced 42.0%
27,200 $7,000
Q1 2022

May 16, 2022

BUY
$0.32 - $0.67 $7,584 - $15,879
23,700 Added 102.16%
46,900 $24,000
Q4 2021

Feb 14, 2022

SELL
$0.6 - $1.11 $5,880 - $10,878
-9,800 Reduced 29.7%
23,200 $14,000
Q3 2021

Nov 12, 2021

SELL
$1.01 - $1.82 $4,545 - $8,190
-4,500 Reduced 12.0%
33,000 $33,000
Q2 2021

Aug 06, 2021

SELL
$1.39 - $2.21 $36,974 - $58,786
-26,600 Reduced 41.5%
37,500 $69,000
Q1 2021

May 14, 2021

SELL
$1.27 - $3.42 $1,397 - $3,762
-1,100 Reduced 1.69%
64,100 $119,000
Q4 2020

Feb 12, 2021

SELL
$0.94 - $1.89 $49,726 - $99,981
-52,900 Reduced 44.79%
65,200 $83,000
Q3 2020

Nov 13, 2020

BUY
$1.5 - $9.38 $133,050 - $832,006
88,700 Added 301.7%
118,100 $233,000
Q2 2020

Aug 13, 2020

BUY
$4.79 - $8.39 $22,513 - $39,433
4,700 Added 19.03%
29,400 $233,000
Q1 2020

May 11, 2020

BUY
$3.44 - $7.21 $39,904 - $83,636
11,600 Added 88.55%
24,700 $136,000
Q4 2019

Feb 12, 2020

SELL
$4.29 - $5.64 $132,990 - $174,840
-31,000 Reduced 70.29%
13,100 $70,000
Q3 2019

Nov 14, 2019

BUY
$4.87 - $7.08 $15,097 - $21,948
3,100 Added 7.56%
44,100 $221,000
Q2 2019

Aug 20, 2019

SELL
$6.6 - $7.8 $27,720 - $32,760
-4,200 Reduced 9.29%
41,000 $284,000
Q1 2019

May 15, 2019

BUY
$5.76 - $8.95 $175,104 - $272,080
30,400 Added 205.41%
45,200 $314,000
Q4 2018

Feb 14, 2019

SELL
$5.26 - $7.97 $84,686 - $128,317
-16,100 Reduced 52.1%
14,800 $87,000
Q3 2018

Nov 14, 2018

SELL
$4.65 - $7.95 $31,155 - $53,265
-6,700 Reduced 17.82%
30,900 $233,000
Q1 2018

May 15, 2018

BUY
$5.6 - $9.25 $210,560 - $347,800
37,600 New
37,600 $229,000

Others Institutions Holding CRBP

About Corbus Pharmaceuticals Holdings, Inc.


  • Ticker CRBP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 125,268,000
  • Market Cap $1.22B
  • Description
  • Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...
More about CRBP
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.